FI3512850T3 - Meniini-mll-interaktion estäjiä - Google Patents
Meniini-mll-interaktion estäjiä Download PDFInfo
- Publication number
- FI3512850T3 FI3512850T3 FIEP17772585.0T FI17772585T FI3512850T3 FI 3512850 T3 FI3512850 T3 FI 3512850T3 FI 17772585 T FI17772585 T FI 17772585T FI 3512850 T3 FI3512850 T3 FI 3512850T3
- Authority
- FI
- Finland
- Prior art keywords
- yyli
- fluori
- pyrrolo
- isopropyyli
- metyyli
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 230000003993 interaction Effects 0.000 title 1
- 208000032839 leukemia Diseases 0.000 claims 27
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 244000207178 Acinos arvensis Species 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 101001109719 Homo sapiens Nucleophosmin Proteins 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100022678 Nucleophosmin Human genes 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395618P | 2016-09-16 | 2016-09-16 | |
| PCT/US2017/051780 WO2018053267A1 (en) | 2016-09-16 | 2017-09-15 | Inhibitors of the menin-mll interaction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3512850T3 true FI3512850T3 (fi) | 2023-06-20 |
Family
ID=59966892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP17772585.0T FI3512850T3 (fi) | 2016-09-16 | 2017-09-15 | Meniini-mll-interaktion estäjiä |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10899758B2 (enExample) |
| EP (2) | EP3512850B1 (enExample) |
| JP (3) | JP2019529421A (enExample) |
| KR (1) | KR102536029B1 (enExample) |
| CN (2) | CN118359610A (enExample) |
| AR (1) | AR109658A1 (enExample) |
| AU (1) | AU2017326006B2 (enExample) |
| CA (1) | CA3036987A1 (enExample) |
| DK (1) | DK3512850T3 (enExample) |
| ES (1) | ES2948949T3 (enExample) |
| FI (1) | FI3512850T3 (enExample) |
| IL (2) | IL265028B (enExample) |
| MX (2) | MX2019003091A (enExample) |
| PL (1) | PL3512850T3 (enExample) |
| TW (1) | TWI757340B (enExample) |
| WO (1) | WO2018053267A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016040330A1 (en) | 2014-09-09 | 2016-03-17 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| AR104020A1 (es) | 2015-06-04 | 2017-06-21 | Kura Oncology Inc | Métodos y composiciones para inhibir la interacción de menina con proteínas mill |
| WO2016197027A1 (en) | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| BR112018068702A2 (pt) | 2016-03-16 | 2019-01-15 | Kura Oncology Inc | inibidores bicíclicos em ponte de menin-mll e métodos de uso |
| CN114539284A (zh) | 2016-03-16 | 2022-05-27 | 库拉肿瘤学公司 | 经取代的menin-mll抑制剂及使用方法 |
| US10899738B2 (en) | 2016-05-02 | 2021-01-26 | The Regents Of The University Of Michigan | Piperidines as menin inhibitors |
| HRP20201771T1 (hr) | 2016-06-10 | 2021-02-19 | Vitae Pharmaceuticals, Llc | Inhibitori interakcije menin-mll |
| AU2017326487B2 (en) | 2016-09-14 | 2021-08-05 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| US10611778B2 (en) | 2016-09-14 | 2020-04-07 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-MLL interaction |
| CA3036987A1 (en) * | 2016-09-16 | 2018-03-22 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| MX391405B (es) | 2016-12-15 | 2025-03-21 | Janssen Pharmaceutica Nv | Inhibidores de azepano de la interacción menina-mll. |
| US11944627B2 (en) | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
| BR112019020130A2 (pt) | 2017-03-31 | 2020-04-22 | Univ Michigan Regents | piperidinas como inibidores covalentes de menin |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| WO2019060365A1 (en) | 2017-09-20 | 2019-03-28 | Kura Oncology, Inc. | SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE |
| JOP20180094A1 (ar) | 2017-10-18 | 2019-04-18 | Hk Inno N Corp | مركب حلقي غير متجانس كمثبط بروتين كيناز |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| JP7250405B2 (ja) * | 2018-01-26 | 2023-04-03 | 塩野義製薬株式会社 | ドーパミンｄ３受容体拮抗作用を有する環式化合物 |
| JP7239562B2 (ja) | 2018-03-30 | 2023-03-14 | 住友ファーマ株式会社 | 光学活性な架橋型環状２級アミン誘導体 |
| EP3845533A4 (en) * | 2018-08-27 | 2022-04-27 | Sumitomo Dainippon Pharma Co., Ltd. | OPTICALLY ACTIVE AZABICYCLIC DERIVATIVE |
| KR102830577B1 (ko) * | 2018-09-13 | 2025-07-08 | 깃세이 야쿠힌 고교 가부시키가이샤 | 이미다조피리디논 화합물 |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| TW202039512A (zh) | 2018-12-06 | 2020-11-01 | 日商第一三共股份有限公司 | 環烷-1,3-二胺化合物 |
| EP4013756B1 (en) * | 2019-09-20 | 2024-05-08 | Novartis AG | Mll1 inhibitors and anti-cancer agents |
| US20220380365A1 (en) * | 2019-09-27 | 2022-12-01 | Sumitomo Dainippon Pharma Co., Ltd. | Crosslinked optically active secondary amine derivative |
| AU2020404305A1 (en) | 2019-12-19 | 2022-08-04 | Janssen Pharmaceutica Nv | Substituted straight chain spiro derivatives |
| AU2020417293A1 (en) | 2020-01-03 | 2022-09-01 | Berg Llc | Polycyclic amides as UBE2K modulators for treating cancer |
| CN111297863B (zh) * | 2020-03-30 | 2021-06-25 | 四川大学华西医院 | menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用 |
| TW202200589A (zh) | 2020-05-28 | 2022-01-01 | 瑞士商諾華公司 | Ｍｌｌ１抑制劑及抗癌劑 |
| TW202239407A (zh) | 2020-12-17 | 2022-10-16 | 瑞典商阿斯特捷利康公司 | Ｎ－（２－（４－氰基四氫噻唑－３－基）－２－側氧基乙基）－喹啉－４－甲醯胺 |
| CN117321049A (zh) | 2021-05-08 | 2023-12-29 | 詹森药业有限公司 | 取代的螺环衍生物 |
| MX2023013176A (es) | 2021-05-08 | 2023-12-01 | Janssen Pharmaceutica Nv | Derivados espiro sustituidos. |
| AU2022274325A1 (en) | 2021-05-14 | 2023-10-05 | Syndax Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| PE20242359A1 (es) | 2021-06-01 | 2024-12-16 | Janssen Pharmaceutica Nv | Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos |
| CA3218340A1 (en) | 2021-06-03 | 2022-12-08 | Janssen Pharmaceutica Nv | Pyridazines or 1,2,4-triazines substituted by spirocyclic amines |
| IL309359A (en) | 2021-06-17 | 2024-02-01 | Janssen Pharmaceutica Nv | (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer |
| CN116903609A (zh) * | 2021-11-05 | 2023-10-20 | 上海优理惠生医药有限公司 | 一种化合物、包含其的药物组合物及其应用 |
| WO2023084320A1 (en) * | 2021-11-11 | 2023-05-19 | V-Ensure Pharma Technologies Private Limited | Reconstitutable, single use antidiabetic compositions |
| WO2023193790A1 (en) * | 2022-04-08 | 2023-10-12 | Janssen Pharmaceutica Nv | Crystalline forms of an inhibitor of the menin/mll interaction |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
| WO2024114658A1 (en) * | 2022-11-30 | 2024-06-06 | Janssen Pharmaceutica Nv | Substituted 1-phenyl-3, 4-dihydropyrido [3, 4-d] pyrimidin-2-one derivatives |
| CN120322230A (zh) * | 2022-11-30 | 2025-07-15 | 詹森药业有限公司 | 包含多发性内分泌癌蛋白-mll抑制剂和至少一种其他治疗剂的组合 |
| JP2025540682A (ja) * | 2022-11-30 | 2025-12-16 | ヤンセン ファーマシューティカ エヌ．ベー． | シクロブチル置換二環式化合物 |
| WO2024114666A1 (en) * | 2022-11-30 | 2024-06-06 | Janssen Pharmaceutica Nv | Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor |
| AR132185A1 (es) * | 2023-03-24 | 2025-06-04 | Acerta Pharma Bv | COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA |
| WO2025067111A1 (zh) * | 2023-09-27 | 2025-04-03 | 苏州必扬医药科技有限公司 | 一种Menin-MLL相互作用抑制剂及其制备方法和应用 |
| WO2025119184A1 (zh) * | 2023-12-04 | 2025-06-12 | 首药控股(北京)股份有限公司 | 取代的多环化合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69928414T2 (de) | 1998-09-18 | 2006-08-03 | Abbott Gmbh & Co. Kg | 4-aminopyrrolopyrimidine als kinaseinhibitoren |
| ATE524467T1 (de) | 2005-04-25 | 2011-09-15 | Merck Patent Gmbh | Neuartige aza-heterozyklen als kinase-inhibitoren |
| WO2010066629A2 (en) | 2008-12-09 | 2010-06-17 | F. Hoffmann-La Roche Ag | Novel azaindoles |
| GB201004311D0 (en) * | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
| TWI500617B (zh) * | 2010-05-31 | 2015-09-21 | Ono Pharmaceutical Co | Purine ketone derivatives |
| US9273056B2 (en) | 2011-10-03 | 2016-03-01 | The University Of North Carolina At Chapel Hill | Pyrrolopyrimidine compounds for the treatment of cancer |
| US8377946B1 (en) * | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| WO2014017659A1 (ja) * | 2012-07-27 | 2014-01-30 | 独立行政法人理化学研究所 | 急性骨髄性白血病の治療又は再発抑制剤 |
| WO2014078578A1 (en) * | 2012-11-15 | 2014-05-22 | Pharmacyclics, Inc. | Pyrrolopyrimidine compounds as kinase inhibitors |
| AU2014279863A1 (en) * | 2013-06-12 | 2016-01-28 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
| EP3057970A1 (en) * | 2013-10-18 | 2016-08-24 | Medivation Technologies, Inc. | Heterocyclic compounds and methods of use |
| US10278979B2 (en) * | 2015-03-11 | 2019-05-07 | Riken | Therapeutic agent for intractable leukemia |
| CA3036987A1 (en) * | 2016-09-16 | 2018-03-22 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
-
2017
- 2017-09-15 CA CA3036987A patent/CA3036987A1/en active Pending
- 2017-09-15 ES ES17772585T patent/ES2948949T3/es active Active
- 2017-09-15 TW TW106131767A patent/TWI757340B/zh active
- 2017-09-15 CN CN202410398451.9A patent/CN118359610A/zh active Pending
- 2017-09-15 EP EP17772585.0A patent/EP3512850B1/en active Active
- 2017-09-15 JP JP2019514787A patent/JP2019529421A/ja not_active Withdrawn
- 2017-09-15 MX MX2019003091A patent/MX2019003091A/es unknown
- 2017-09-15 PL PL17772585.0T patent/PL3512850T3/pl unknown
- 2017-09-15 IL IL265028A patent/IL265028B/en unknown
- 2017-09-15 WO PCT/US2017/051780 patent/WO2018053267A1/en not_active Ceased
- 2017-09-15 KR KR1020197010730A patent/KR102536029B1/ko active Active
- 2017-09-15 CN CN201780063763.2A patent/CN110325533B/zh active Active
- 2017-09-15 EP EP23167055.5A patent/EP4230627A3/en active Pending
- 2017-09-15 AR ARP170102556A patent/AR109658A1/es active IP Right Grant
- 2017-09-15 IL IL295972A patent/IL295972A/en unknown
- 2017-09-15 FI FIEP17772585.0T patent/FI3512850T3/fi active
- 2017-09-15 AU AU2017326006A patent/AU2017326006B2/en active Active
- 2017-09-15 DK DK17772585.0T patent/DK3512850T3/da active
- 2017-09-15 US US16/333,852 patent/US10899758B2/en active Active
-
2019
- 2019-03-15 MX MX2022013841A patent/MX2022013841A/es unknown
-
2020
- 2020-08-11 US US16/990,657 patent/US11739085B2/en active Active
-
2022
- 2022-10-06 JP JP2022161777A patent/JP2022189853A/ja active Pending
-
2023
- 2023-05-18 US US18/320,111 patent/US20240124447A1/en not_active Abandoned
-
2024
- 2024-11-08 JP JP2024195965A patent/JP2025022910A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3512850T3 (fi) | Meniini-mll-interaktion estäjiä | |
| FI3704120T3 (fi) | Heterosyklisiä yhdisteitä prmt5:n estäjinä | |
| FI3723783T3 (fi) | Mitokondrioon kohdentuvia peptidejä | |
| FI3672975T3 (fi) | Kondensoituja heterosyklisiä johdannaisia bcl-2-inhibiittoreina neoplastisten sairauksien hoitamiseksi | |
| IL265700B1 (en) | N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4 -tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea and its uses | |
| HUE053643T2 (hu) | (S)-N-(5 -((R)-2-(2,5-difluor-fenil)-pirrolidin-1-il)-pirazolo[1,5-A] pirimidin-3-il)-3-hidroxi-pirrolidin-1-karboxamid elõkészítése | |
| IL262003A (en) | Liquid formulations of (s)-n-(5-((r)-2-(5,2-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[5,1-a]pyrimidin-3-yl)-3 -Hydroxypyrrolidine-1-carboxamide | |
| CL2009001884A1 (es) | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. | |
| CL2008003023A1 (es) | (s)-4-amino-n-(1-(4-clorofenil)-3-hidroxipropil)-1-(7h-pirrolo[2,3-d]pirimidin-4-il)piperidina-4-carboxamida, inhibidor de la proteina quinasa b; procedimiento de preparacion; compuestos intermediarios; composicion farmacéutica que comprende dicho compuesto; y uso para el tratamiento del cancer. | |
| IL254132B (en) | A solid preparation of N-(4-(1(2,6-difluorobenzyl)-5-))dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxy-1,2,3 4-tetrahydrothiano[2,3-d]pyrimidine-6-yl)phenyl)-n-methoxyurea or its salt | |
| MA37316A1 (fr) | Dérivés de 2-amino, 6-phenyl à substitution pyrido [2, 3 - d] pyrimidine utilisés en tant qu'inhibiteurs de la raf kinase | |
| CL2008002131A1 (es) | Compuestos heterociclos de amidas derivados de pirimidinas sustituidas por heterociclos y heterobiciclicos, inhibidores de la proteincinasa; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades proliferativas, neurologicas o neurodegenerativas, cardiovasculares, virosica o fungicas. | |
| FI4103566T3 (fi) | Sulautettuja pyrimidiiniyhdisteitä kcc2-modulaattoreina | |
| MX2022015003A (es) | Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina. | |
| WO2019229536A3 (en) | Novel benzodiazepine derivatives and uses thereof | |
| EP3882247A4 (en) | SIX-MEMBERED, SIX-MEMBERED, HETEROCYCLIC COMPOUND AND USES OF THEREOF AS A PROTEIN KINASE RECEPTOR INHIBITOR | |
| HUE072069T2 (hu) | 2-((1R,4R)-4-((3-(3-(trifluormetil)fenil)imidazo[1,2- b]piridazin-6-il)amino)ciklohexil)propán-2-ol sósavas sójának kristályos formája | |
| WO2016032209A3 (ko) | 야누스인산화효소 억제제로서의 치환된 n-(피롤리딘-3-일)-7h-피롤로[2,3-d]피리미딘-4-아민 | |
| EP3730492A4 (en) | COMPOUND PYRAZOLO [1,5-A] PYRIMIDINE SUBSTITUTE, PHARMACEUTICAL COMPOSITION AND ASSOCIATED USE | |
| MX2020002505A (es) | Compuestos heteroaromaticos sustituidos con cicloolefinas y su uso. | |
| PL3759113T3 (pl) | Pochodne 10-(di(fenylo)metylo)-4-hydroksy-8,9,9a,10-tetrahydro-7h- pirolo[1’,2’:4,5]pirazyno[1,2-b]pirydazyno-3,5-dionowe i związki pokrewne jako inhibitory replikacji ortomyksowirusów do leczenia grypy | |
| MX2021002794A (es) | Metodo mejorado para la fabricacion de 3-[(1s)-1-imidazo[1,2-a]pir idin-6- iletil]-5-(1-metilpirazol-4-il)triazolo[4,5-b]pirazina y formas polimorficas de la misma. | |
| AU2018375456A1 (en) | Thieno(3,2-d)pyrimidine compound having inhibitory activity for protein kinase | |
| LT3655395T (lt) | N-((1r,2s,sr)-5-(tret-butilamino)-2-((s)-3-(7-tret-butilpirazolo[1,5-a][1,3,5]triazin-4-ilamino)-2-oksopirolidin-1-il)cikloheksil)acetamido gamybos būdas | |
| GB201910656D0 (en) | New use of triazolo(4,5-d)Pyrimidine deerivatives |